Previous 10 | Next 10 |
2024-04-22 12:11:08 ET Summary As known, compound interest is the mechanism of earning interest on both the principal amount and the accumulated interests. Automatic reinvestment of dividends can passively trigger this mechanism for any security in our income portfolio. While ...
MENLO PARK, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of t...
MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of th...
2024-04-14 09:11:39 ET Summary Cash is becoming more appealing as the market continues to hit all-time highs, but there are still some potential opportunities. I consistently make purchases every month regardless of market conditions, though I tend to slow down a bit when we are r...
2024-04-09 09:00:15 ET John Hancock Tax- Advantaged Dividend Income (HTD) declaring a stock dividend of $0.138 per share on Ex-Date : April 10, 2024. Shareholders on record as of April 11, 2024 are eligible for the dividend. The payment date is scheduled for April 30, 2024, and the ...
MENLO PARK, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of th...
MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of th...
2024-03-21 10:52:38 ET Summary John Hancock Tax-Advantaged Dividend Income Fund is back trading at an attractive relative and absolute discount. The HTD closed-end fund offers exposure to utility and fixed-income/preferred securities, which should perform well going forward after ...
2024-03-18 23:34:32 ET Summary Surrounded by the smoothness of the Tuscan landscape, I have always thought that the pursuit of harmony in human activities is the first step toward happiness. I also chase a balance in investments, seeking to create a portfolio whose securities prov...
2024-03-13 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest Company Name:
HTD Stock Symbol:
NYSE Market:
2024-07-12 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 05:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Results from the CATALYST clinical trial were presented at the American Diabetes Association’s 84 th Scientific Sessions at a featured plenary session titled: “Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes” With 1,055 patients enro...